<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939977</url>
  </required_header>
  <id_info>
    <org_study_id>ACA-SPAI-11-24</org_study_id>
    <secondary_id>2013-001326-25</secondary_id>
    <nct_id>NCT01939977</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.</brief_title>
  <acronym>PARIDOINAL2013</acronym>
  <official_title>Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Senefro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Effice Servicios Para la Investigacion S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Senefro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation
      (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D
      nutritional supplements (calcifediol) in patients with renal transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the superiority of paricalcitol treatment at
      early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone)
      compared to the use of vitamin D nutritional supplements (calcifediol) in patients with renal
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with iPTH serum concentration &gt;110 pg/mL.</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients with iPTH serum concentration &gt;110 pg/mL post transplantation and 6 month after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on iPTH serum concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Change on iPTH serum concentration on each treatment group 6 month post transplantation and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least iPTH≥30% of reduction from basal level.</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that reach at least a 30% iPTH reduction at the end of the study.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with iPTH levels between 70-110 pg/mL at the end of the study.</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient with presence of calcifications on protocol renal biopsies at 6 months after treatment en each treatment group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, compared and separate, of each of the following events: acute rejection, acute rejection confirmed with biopsy and/or subclinic rejection and/or chronic damage.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of alloreactive T memory cells against donor's antigen at 6 months after treatment en each treatment group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on concentration of bone markers (alkaline phosphatase and osteocalcin) and FGF-23 (Fibroblast growth factor 23) at 6 months after transplantation and treatment on each treatment group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with acute rejection at 6 months after transplantation and treatment on each treatment group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with delayed graft function at 6 months after treatment en each treatment group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with microalbuminuria on months 1, 3 and 6 post transplantation.</measure>
    <time_frame>Months 1, 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients on each stage of renal function on months 1, 3 and 6 post transplantation.</measure>
    <time_frame>Months 1, 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of blood pressure, speed of pulse wave, calcium-phosphorus metabolic parameters throughout the study and evolution of bone mineral density at 6 post transplantation.</measure>
    <time_frame>6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with hypercalcemia on each treatment group at 6 months post transplantation.</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients with hypercalcemia (defined as serum calcium levels &gt; 10,3 mg/dl) on each treatment group at 6 months post transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of anti-HLA antibodies (PRA) from basal to month 6 post-transplantation.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events or serious adverse events that occurs during the study on each treatment group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Secondary Hyperparathyroidism Due to Renal Causes</condition>
  <arm_group>
    <arm_group_label>Paricalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol oral capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcifediol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcifediol oral drops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.</description>
    <arm_group_label>Paricalcitol</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol</intervention_name>
    <description>5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.</description>
    <arm_group_label>Calcifediol</arm_group_label>
    <other_name>Hidroferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient that have willingly signed and dated the ICD (Informed Consent Document)
             approved by the EC (Ethics Committee) before any study procedure and after they have
             been explained the study, they have read the ICD and have had the opportunity to make
             questions about it.

          -  Patients of both genders and older than 18 years candidates to an immediately renal
             transplantation from living or deceased donor.

          -  24 hours previous to the transplantation, patient must have a significant grade of
             secondary hyperparathyroidism, defined as iPTH levels between 110 and 600 pg/mL as per
             central laboratory results.

          -  Patients with a preformed antibody panel &lt;20% 24 hours before the transplantation or
             that are considered by the investigator of low immunological risk (PRA determination
             is being done on local laboratory, not central).

          -  Serum calcium (corrected by albumin) &lt; 10 mg/dL 24 hour previous to the
             transplantation as per central laboratory results.

          -  Patients that are to be treated with immunosuppression based on tacrolimus, mofetil
             mycofenolate or mycophenolic acid and with steroids and that are not going to be
             treated with mTOR (mammalian target of rapamycin) inhibitors. Tacrolimus and steroids
             must not be removed on the 6 month post-transplantation.

          -  Patients that are able to take oral capsules on the first week post-transplantation.

        Exclusion Criteria:

          -  Third or subsequent renal transplantation.

          -  Positive cross-match assay or ABO (A-B-0) incompatibility

          -  Patients that have been or are going to be recipients of other organs other than the
             kidney or a double kidney transplantation.

          -  Patients with history of allergic reaction or sensibility to paricalcitol, calcifediol
             or similar study drugs (related with vitamin D).

          -  Patients with chronic gastrointestinal disease, that, based on investigators criteria,
             can cause significant gastrointestinal malabsorption.

          -  Patient with hypo or hyperthyroidism not controlled based on investigators criteria.

          -  Patient with uncontrolled hypertension based on investigators criteria.

          -  Patients that, 48 hours previous to transplantation, have been receiving
             calcimimetics.

          -  Patients with VIH (human immunodeficiency virus)infection of positive serology for HBV
             (hepatitis B virus) and/or HCV (hepatitis C virus)

          -  Patients on treatment with drugs contraindicated with paricalcitol and calcifediol
             (based on SMPC)

          -  Patients that are participating on other clinical trial with investigational drugs.

          -  Women of childbearing potential (defined as those whose last menstruation was &lt;2 years
             ago and that are not surgically sterilized) that are not willing to use correct
             contraception during study treatment.

          -  Patient with other diseases or conditions that based on investigators criteria are not
             suitable for the study.

          -  Treatment will not be started if the Calcium-Phosphorus product (CAxP)is &gt;55 mg2/dL2
             or in case of hyperphosphatemia considered significant as per investigator criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep M Cruzado, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación SENEFRO - Hospital Universitario de Bellvitge - Barcelona.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol de Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Canarias</name>
      <address>
        <city>San Cristobal de La Laguna</city>
        <state>Las Palmas de Gran Canaria</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Puigvert-Iuna</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta Del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>September 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>Hyperparathyroidism Secondary</keyword>
  <keyword>Paricalcitol</keyword>
  <keyword>Calcifediol</keyword>
  <keyword>Parathyroid hormone</keyword>
  <keyword>Renal transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 8, 2017</submitted>
    <returned>October 2, 2017</returned>
    <submitted>May 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

